Navigation Links
PharmaNet Announces Tender Offer and Consent Solicitation
Date:5/27/2011

ay be directed to D.F. King & Co., Inc., the Information Agent, at (800) 967-4607 (toll free).

This press release is for information purposes only and does not constitute an offer to purchase the Notes, a solicitation of an offer to purchase the Notes or a solicitation of a consent to amend the related indenture. The Offer is made solely pursuant to the Offer to Purchase. The Offer is not being made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.

None of the Company, the Dealer Managers and Solicitation Agents, the Information Agent or any other person makes any recommendation as to whether holders of Notes should tender their Notes, and no one has been authorized to make such a recommendation.

COMPANY INFORMATION AND FORWARD LOOKING STATEMENTS

PharmaNet is a leading provider of integrated product development services and provides clinical development services, including consulting, Phase I and bioequivalency clinical studies, and Phase II, III and IV clinical development programs, to pharmaceutical, biotechnology, generic drug and medical device companies around the world.

This press release contains forward-looking statements which include, but are not limited to, any statement that may predict, forecast, indicate or imply future results, performance, achievements or events. Forward-looking statements are based upon management's current plans and beliefs or current estimates of future results or trends. These forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that may cause actual results to differ materially from trends, plans or expectations set forth in the forward-looking statements.

Given these risks and uncertainties, we urge you to read the tender offer materials completely and wi
'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PharmaNet to Present More Than 20 Posters at the 2010 American Association of Pharmaceutical Scientists Annual Meeting
2. PharmaNet Development Group Experts to Share Insights at the 9th Annual Partnerships in Clinical Trials Conference in Vienna
3. PharmaNet Development Group Appoints Anthony Maida, Vice President, Clinical Research
4. Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
5. SEC Closes Investigation of PharmaNet Development Group and Recommends No Action
6. Christopher Brennan Joins PharmaNet Development Group as General Counsel
7. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
8. PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June
9. PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes
10. PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
11. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014  Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/11/2014)... 2014 Cayenne Medical, Inc., a ... the soft tissue reconstruction segment, announced the worldwide ... surgeries involving the shoulder and extremities. The SureLock ... inserter-controlled deployment method. The unique delivery eliminates manual ... pull-out, or anchor displacement (also commonly know as ...
(Date:7/10/2014)... Burkina Faso (PRWEB) July 10, 2014 ... Faso, today have access to an additional family ... increase access to contraception at all levels of ... a lower-dose formulation of a widely used contraceptive—Pfizer’s ... system. , Burkina Faso is the first of ...
(Date:7/10/2014)... 10, 2014 Product and process ... low abundance and are often “lost in the ... , Join presenters Dr. Rowel Tobias, Senior Scientist, ... Anders, Head of Quality at Nanotherapeutics, Inc., to ... can speed detection and quantitation while achieving the ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2
... allows up to 50% sucrose reduction while maintaining the sweet taste ... ... CA, July 29, 2008 Senomyx, Inc.,(Nasdaq: SNMX ), a ... flavor ingredients for the food, beverage,and ingredient supply industries, announced today ...
... technology to an,orphan disease, in a unique translational ... July 29 ,ALS Therapy Development Institute (ALS TDI) ... new collaboration aimed at advancing any potential,application of ... sclerosis,commonly known as Lou Gehrig,s diseases. The new ...
... Zenobia Therapeutics, Inc.,(Zenobia) announced today that ... from The Michael J. Fox Foundation for ... potential to,fundamentally alter the course of Parkinson,s ... Ross of Johns Hopkins University,Zenobia will discover ...
Cached Biology Technology:SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 2SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 3SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 4ALS Therapy Development Institute and California Stem Cell, Inc. Announce Long-Term Scientific Collaboration 2ALS Therapy Development Institute and California Stem Cell, Inc. Announce Long-Term Scientific Collaboration 3Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2 2
(Date:7/11/2014)... study the proteins that let nerve cells send out ... upon a biological tactic that may offer a new ... safe and environmentally responsible way. , Their findingthat ... species and harmless for a closely related onesuggests that ... harming beneficial species like bees. A summary of the ...
(Date:7/11/2014)... of all vertebrates, information is transmitted through synapses, ... signal to be passed from one brain cell ... abundant type of synapse, can be either excitatory ... memory, perception and cognition, and the balance between ... For instance, every time we learn something, ...
(Date:7/10/2014)... In Santa Fe, Albuquerque, and other major cities in ... watered with treated municipal wastewater rather than precious potable ... more than 40% of all golf courses receive treated ... courses. , Additionally, golf courses and homeowners alike ... nutrient in fertilizer is nitrate. A New Mexico State ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3Blame it on the astrocytes 2'Tailored' water -- the latest in lawn care 2
... Lee Lovering, Ph.D., School of Biosciences, University of ... Award for his seminal work on the structural ... and modify cell walls in bacteria. Natalie Strynadka, ... Lovering,s work: "his spectacular abilities in structural biology ...
... 2012) Aeras and the Infectious Disease Research Institute ... trial of IDRI,s novel tuberculosis vaccine candidate, ID93 + ... safety, tolerability and immunogenicity of the vaccine candidate in ... by Johnson County Clin-Trials in Lenexa, Kansas, in close ...
... risks posed to people who work with tiny fibres used ... Research into the health risks posed by nanofibres ... has pinpointed the lengths at which these fibres are ... from a range of materials including carbon, are about 1,000 ...
Cached Biology News:The American Society for Microbiology honors Andrew Lovering 2As TB grows more difficult to control, vaccine candidate to prevent disease enters clinical testing 2